用促红细胞生成素治疗早产儿不会增加早产儿视网膜病变的风险。 - Suppr

Suppr

超能文献

Treating preterm infants with erythropoietin does not increase the risk of retinopathy of prematurity.

作者信息

Bahr Timothy M, Ohls Robin K, Christensen Robert D

机构信息

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, UT, USA.

Women and Newborns Research Program, Intermountain Healthcare, Salt Lake City, UT, USA.

出版信息

J Perinatol. 2025 Feb;45(2):292-293. doi: 10.1038/s41372-024-02047-6. Epub 2024 Jul 18.

DOI:10.1038/s41372-024-02047-6

PMID:39025955

Abstract

摘要

相似文献

Treating preterm infants with erythropoietin does not increase the risk of retinopathy of prematurity.用促红细胞生成素治疗早产儿不会增加早产儿视网膜病变的风险。

J Perinatol. 2025 Feb;45(2):292-293. doi: 10.1038/s41372-024-02047-6. Epub 2024 Jul 18.

Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants.早期预防性低剂量重组人促红细胞生成素对极早产儿早产儿视网膜病变的影响。

J Transl Med. 2020 Oct 19;18(1):397. doi: 10.1186/s12967-020-02562-y.

Early Erythropoietin Administration does not Increase the Risk of Retinopathy in Preterm Infants.早期使用促红细胞生成素不会增加早产儿视网膜病变的风险。

Pediatr Neonatol. 2017 Feb;58(1):48-56. doi: 10.1016/j.pedneo.2016.03.006. Epub 2016 Jun 1.

Use of erythropoietin is associated with threshold retinopathy of prematurity (ROP) in preterm ELBW neonates: a retrospective, cohort study from two large tertiary NICUs in Italy.促红细胞生成素的使用与极低出生体重早产儿的阈值性早产儿视网膜病变（ROP）相关：一项来自意大利两家大型三级新生儿重症监护病房的回顾性队列研究。

Early Hum Dev. 2014 Sep;90 Suppl 2:S29-33. doi: 10.1016/S0378-3782(14)50009-6.

Asymptomatic late thrombocytosis is a common finding in very preterm infants even in the absence of erythropoietin treatment.无症状性晚期血小板增多症在极早产儿中很常见，即使未接受促红细胞生成素治疗也是如此。

J Int Med Res. 2019 Apr;47(4):1504-1511. doi: 10.1177/0300060518821033. Epub 2019 Feb 8.

The relationship of the subtypes of preterm birth with retinopathy of prematurity.早产亚型与早产儿视网膜病变的关系。

Am J Obstet Gynecol. 2017 Sep;217(3):354.e1-354.e8. doi: 10.1016/j.ajog.2017.05.029. Epub 2017 May 22.

Erythropoietin is not a risk factor for severe retinopathy of prematurity among high risk preterm infants.促红细胞生成素不是高危早产儿重度早产儿视网膜病变的危险因素。

Early Hum Dev. 2021 Oct;161:105440. doi: 10.1016/j.earlhumdev.2021.105440. Epub 2021 Aug 8.

Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.早期使用促红细胞生成素预防早产和/或低出生体重儿的红细胞输血。

Cochrane Database Syst Rev. 2012 Sep 12(9):CD004863. doi: 10.1002/14651858.CD004863.pub3.

Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity.重组促红细胞生成素的较高累积剂量与早产儿视网膜病变风险之间的关联。

J AAPOS. 2006 Apr;10(2):143-9. doi: 10.1016/j.jaapos.2005.09.005.

Endogenous erythropoietin concentrations and association with retinopathy of prematurity and brain injury in preterm infants.内源性促红细胞生成素浓度与早产儿视网膜病变和脑损伤的关系。

PLoS One. 2021 Jun 2;16(6):e0252655. doi: 10.1371/journal.pone.0252655. eCollection 2021.

引用本文的文献

Involving neonatal hematology and transfusion medicine in global efforts to eliminate severe retinopathy of prematurity.让新生儿血液学和输血医学参与到全球消除早产儿严重视网膜病变的努力中。

J Perinatol. 2025 Jul 23. doi: 10.1038/s41372-025-02368-0.

本文引用的文献

A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.早产儿红细胞生成素神经保护的随机试验。

N Engl J Med. 2020 Jan 16;382(3):233-243. doi: 10.1056/NEJMoa1907423.

Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates.促红细胞生成素刺激剂在新生儿中显示出安全性，并有望成为神经保护剂。

J Pediatr. 2015 Jul;167(1):10-2. doi: 10.1016/j.jpeds.2015.03.054. Epub 2015 Apr 25.

Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?重组人促红细胞生成素和铁补充剂会增加早产儿视网膜病变的风险吗？

Eur J Pediatr. 2000 Aug;159(8):627-8. doi: 10.1007/pl00008390.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验